Xdemvy®
Lotilaner 0.25% · ophthalmic solution
Dry Eye/OSD
Approved uses
Demodex blepharitis
1 drop in each eye BID, approximately 12 hours apart, for 6 weeks
Collarette cure in about half of patients by week 6, with most clearing to 10 or fewer collarettes.
Contraindications
None.
0.25% (2.5 mg/mL) solution, 10 mL multiple-dose dropper bottle; 1.5 mL dropper bottle as a physician sample
Ectoparasiticide that inhibits GABA-gated chloride channels selective for mites, producing paralysis and death of Demodex. Not an inhibitor of mammalian GABA-mediated chloride channels when tested in vitro up to 30 micromolar, roughly 1100 times the recommended human ophthalmic dose.
Warnings & Precautions
- Risk of contamination: Tip contact with the eye, surrounding structures, fingers, or any surface can contaminate the solution, and serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
- Use with contact lenses: Remove lenses before instillation and reinsert 15 minutes afterward; the potassium sorbate preservative may discolor soft lenses.
Common Side Effects
- Ocular, most common: Instillation-site stinging and burning 10% (833 patients treated for 42 days in Saturn-1 and Saturn-2).
- Ocular, under 2%: Chalazion or hordeolum, punctate keratitis.
- Tolerability, Saturn-2: 90.7% of patients rated the drop neutral to very comfortable, with mean compliance 98.7%.
Pregnancy: No human data; systemic exposure after ocular dosing is low and animal reproduction studies produced no malformations at clinically relevant doses. Oral dosing in rats increased post-implantation loss and reduced fetal weight with incomplete ossification only at 1390 times the recommended human ophthalmic dose on a body surface area basis and in the presence of maternal toxicity, with one fetus at that dose showing situs inversus that could not be excluded as treatment related; rabbits showed no embryofetal toxicity or teratogenic findings at 580 times the human dose on an AUC basis.
Lactation: No data on presence in human milk, effects on the breastfed infant, or milk production; systemic exposure after 6 weeks of topical dosing is low and the drug is more than 99% plasma protein bound. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for the drug and any potential adverse effects on the breast-fed child.
Safety and effectiveness not established below age 18.